Volume 31, Issue 1 (April 2020)
Studies in Medical Sciences 2020, 31(1): 66-74 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rajabi A, Emami A, Safaralizadeh R. EVALUATION OF ELTD1 GENE EXPRESSION IN MELATONIN-TREATED HT29 CANCER CELLS: AN EXPERIMENTAL BIOINFORMATICS STUDY. Studies in Medical Sciences 2020; 31 (1) :66-74
URL: http://umj.umsu.ac.ir/article-1-5011-en.html
URL: http://umj.umsu.ac.ir/article-1-5011-en.html
Associate Professor, Department of Genetics, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran (Corresponding Author) , safaralizadeh@tabrizu.ac.ir
Abstract: (3646 Views)
Background & Aims: Colorectal cancer after lung and breast cancer is the most common cause of death. The ELTD1 gene encodes a G-protein-binding protein that acts as a growth factor receptor and plays a role in normal angiogenesis as well as in cancer cells. The aim of this study was to evaluate the ELTD1 gene expression in melatonin treated HT29 cancer cells using bioinformatics and experimental approaches.
Materials & Methods: First, microarray data were provided from Gene Expression Omnibus (GEO) and then they were analyzed using Probabilistic neural networks (PNN) in MATLAB 2018a software as a bioinformatics tool. The cytotoxicity of melatonin was assessed by MTT assay. Subsequently, Q-RT-PCR was employed to evaluate the rate of ELTD1 gene expression in HT29 cells treated with melatonin.
Results: The bioinformatics analysis indicated that ELTD1 expression level considerably decreased in cells exposed to melatonin in comparison to control group. MTT assay demonstrated that melatonin reduced HT29 cell viability in a concentration and time-dependent manner and the IC50 values of melatonin were calculated to be 160 µM in 48h. In addition, analyzing Q-RT-PCR indicated that melatonin significantly decreased ELTD1 expression level which is supported by bioinformatics analysis results.
Conclusion: The results indicated that ELTD1 gene can be used as a target gene for melatonin in colorectal cancer therapy. However, more study is needed to prove our results
Materials & Methods: First, microarray data were provided from Gene Expression Omnibus (GEO) and then they were analyzed using Probabilistic neural networks (PNN) in MATLAB 2018a software as a bioinformatics tool. The cytotoxicity of melatonin was assessed by MTT assay. Subsequently, Q-RT-PCR was employed to evaluate the rate of ELTD1 gene expression in HT29 cells treated with melatonin.
Results: The bioinformatics analysis indicated that ELTD1 expression level considerably decreased in cells exposed to melatonin in comparison to control group. MTT assay demonstrated that melatonin reduced HT29 cell viability in a concentration and time-dependent manner and the IC50 values of melatonin were calculated to be 160 µM in 48h. In addition, analyzing Q-RT-PCR indicated that melatonin significantly decreased ELTD1 expression level which is supported by bioinformatics analysis results.
Conclusion: The results indicated that ELTD1 gene can be used as a target gene for melatonin in colorectal cancer therapy. However, more study is needed to prove our results
References
1. Houlston R. What we could do now: molecular pathology of colorectal cancer. Mol Pathol. 2001;54(4):206. [DOI:10.1136/mp.54.4.206] [PMID] [PMCID]
2. Zinzindohoué F, Lecomte T, Ferraz J-M, Houllier A-M, Cugnenc P-H, Berger A, et al. Prognostic significance of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer. Clin Cancer Res 2005;11(2):594-9. [DOI:10.1158/1078-0432.594.11.2] [PMID]
3. Abedi-Gaballu F, Dehghan G, Ghaffari M, Yekta R, Abbaspour-Ravasjani S, Baradaran B, et al. PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy. Appl Mater Today 2018;12:177-90.HT29 ELTD1 [DOI:10.1016/j.apmt.2018.05.002] [PMID] [PMCID]
4. Abedi-Gaballu F, Abbaspour-Ravasjani S, Mansoori B, Yekta R, Hamishehkar H, Mohammadi A, et al. Comparative of in vitro evaluation between erlotinib loaded Nanostructured lipid carriers and liposomes against A549 lung cancer cell line. Iran J Pharm Res 2019;18(3):1168-79. [PMID] [PMCID]
5. Anisimov VN. The role of pineal gland in breast cancer development. Crit Rev Oncol Hematol 2003;46(3):221-34. [DOI:10.1016/S1040-8428(03)00021-0] [PMID]
6. Zare H, Shafabakhsh R, Reiter RJ, Asemi Z. Melatonin is a potential inhibitor of ovarian cancer: molecular aspects. J Ovarian Res2019;12(1):26. [DOI:10.1186/s13048-019-0502-8] [PMID] [PMCID]
7. da Silva NRJ, Laste G, Deitos A, Stefani LC, Cambraia-Canto G, Torres IL, et al. Combined neuromodulatory interventions in acute experimental pain: assessment of melatonin and non-invasive brain stimulation. Front Behav Neurosci 2015;9:77. [DOI:10.3389/fnbeh.2015.00077] [PMID] [PMCID]
8. Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, Ostrom RS, Slominski AT. Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol 2012;351(2):152-66. [DOI:10.1016/j.mce.2012.01.004] [PMID] [PMCID]
9. Bhattacharya S, Patel KK, Dehari D, Agrawal AK, Singh S. Melatonin and its ubiquitous anticancer effects. Mol Cell Biochem 2019:1-23. [DOI:10.1007/s11010-019-03617-5] [PMID]
10. Becker-André M, Wiesenberg I, Schaeren-Wiemers N, Andre E, Missbach M, Saurat J-H, et al. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J Biol Chem 1994;269(46):28531-4. [DOI:10.1016/S0021-9258(19)61934-4] [PMID]
11. Kan A, Le Y, Zhang Y-f, Duan F-t, Zhong X-p, Lu L-h, et al. ELTD1 Function in Hepatocellular Carcinoma is Carcinoma-Associated Fibroblast-Dependent. J Cancer 2018;9(14):2415. [DOI:10.7150/jca.24406] [PMID] [PMCID]
12. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324(1):1-8. [DOI:10.1056/NEJM199101033240101] [PMID]
13. Yao H, Liu N, Lin MC, Zheng J. Positive feedback loop between cancer stem cells and angiogenesis in hepatocellular carcinoma. Cancer Lett 2016;379(2):213-9. [DOI:10.1016/j.canlet.2016.03.014] [PMID]
14. Gladitz J, Klink B, Seifert M. Network-based analysis of oligodendrogliomas predicts novel cancer gene candidates within the region of the 1p/19q co-deletion. Acta Neuropathol Commun2018;6(1):49. [DOI:10.1186/s40478-018-0544-y] [PMID] [PMCID]
15. Sonehara NM, Lacerda JZ, Jardim‑Perassi BV, de Paula Jr R, Moschetta‑Pinheiro MG, Souza YST, et al. Melatonin regulates tumor aggressiveness under acidosis condition in breast cancer cell lines. Oncol Lett 2019;17(2):1635-45. [DOI:10.3892/ol.2018.9758] [PMID] [PMCID]
16. Sun W, Yang J. Functional mechanisms for human tumor suppressors. J Cancer 2010;1:136. [DOI:10.7150/jca.1.136] [PMID] [PMCID]
17. Wasserman PD. Advanced methods in neural computing: John Wiley & Sons, Inc.; 1993. [Google Scholar]
18. Chen B-J, Wu Y-L, Tanaka Y, Zhang W. Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics. Int J Biol Sci 2014;10(10):1084. [DOI:10.7150/ijbs.10190] [PMID] [PMCID]
19. Zhang T, Guo J, Gu J, Wang Z, Wang G, Li H, et al. Identifying the key genes and microRNAs in colorectal cancer liver metastasis by bioinformatics analysis and in vitro experiments. Oncol Rep 2019;41(1):279-91. [DOI:10.3892/or.2018.6840]
20. Towner RA, Jensen RL, Colman H, Vaillant B, Smith N, Casteel R, et al. ELTD1, a potential new biomarker for gliomas. Neurosurgery 2012;72(1):77-91. [DOI:10.1227/NEU.0b013e318276b29d] [PMID] [PMCID]
21. Laothong U, Hiraku Y, Oikawa S, Intuyod K, Murata M, Pinlaor S. Melatonin induces apoptosis in cholangiocarcinoma cell lines by activating the reactive oxygen species-mediated mitochondrial pathway. Oncol Rep 2015;33(3):1443-9. [DOI:10.3892/or.2015.3738] [PMID]
22. Yun S-M, Woo SH, Oh ST, Hong S-E, Choe T-B, Ye S-K, et al. Melatonin enhances arsenic trioxide-induced cell death via sustained upregulation of Redd1 expression in breast cancer cells. Mol Cell Endocrinol 2016;422:64-73. [DOI:10.1016/j.mce.2015.11.016] [PMID]
23. Abedi Gaballu F, Mansoori B, Dehghan G. Study of hmga2 gene inhibition with specific shrna and sirna and investigation of corresponding effects on downstream gene expression in mda-mb-231 cancer cells: a bioinformatic and experimental study. Urmia Med J 2019;30(6):475-86. [Google Scholar]
24. Li J, Shen J, Wang Z, Xu H, Wang Q, Chai S, et al. ELTD1 facilitates glioma proliferation, migration and invasion by activating JAK/STAT3/HIF-1α signaling axis. Sci Rep 2019;9(1):1-12. [DOI:10.1016/0920-2307(92)90011-O]
25. Ziegler J, Zalles M, Smith N, Saunders D, Lerner M, Fung K-M, et al. Targeting ELTD1, an angiogenesis marker for glioblastoma (GBM), also affects VEGFR2: molecular-targeted MRI assessment. Am J Nucl Med Mol Imaging 2019;9(1):93. [PMCID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
